Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

GW Pharmaceuticals data the "most convincing so far", says City heavyweight

Earlier this month investors were put on bid alert after a report suggest the company had multiple potential suitors.
GW Pharmaceuticals data the "most convincing so far", says City heavyweight
GW is a specialist in cannabis-derived medicines.

“Impressive so far”, is the verdict of one leading City broker, referring to the progress of GW Pharmaceuticals PLC (LON:GWP, NASDAQ:GWPH) and the results from its lead drug for a childhood epilepsy.

Numis, in a note, repeated its 835p valuation of stock in the druggie, which is at the cutting edge of cannabis-derived medicines.

The shares ended the week at 838.5p, up 20%.

The driver? GW unveiled more pointers to the efficacy of Epidolex, for childhood seizures.

Numis analyst Paul Cuddon called it “the most convincing ”data so far.

It is expected GW will make a new drug application early next year.

Earlier this month investors were put on bid alert after a report suggest the company had multiple potential suitors.

The Reuters story also said GW had appointed Wall Street heavyweight Morgan Stanley to oversee the potential beauty parade.

The interest was very firmly rooted around Epidiolex, which analysts reckon has the potential to deliver annual sales of around US$800mln.

The identities of the potential suitors were unknown.

However, the big beasts in this sphere of the drugs market are Novartis (ETX:NOVN), Bayer (ETR:BAYN) and Almirall (BME:ALM).

Numis, in an earlier broker note, reckoned Lundbeck (CPH:LUN), Otsuka (TYO:4578) and Biogen (NASDAQ:BIIB) might also be in the running.

In the year to date the stock has advanced 102%, buoyed by some encouraging headline results from a phase III clinical trial of Epidiolex.

On the back of that the company was able to raise £190mln from US investors to bankroll the further development of its lead product.

Valued at £2.4bn, GW is AIM’s third largest company.

View full GWP profile View Profile

GW Pharmaceuticals Timeline

Related Articles

viagra.jpg
May 31 2017
Written responses from America’s Food & Drug Administration and the Medicines & Healthcare products Regulatory Agency (MHRA) here in Britain support its timeline, which sees marketing approval for the product in the second-quarter of 2019.
Picture of drugs
July 18 2017
Gross profit in the half year to December was up by 34%
e-Therapeutics
Thu
E-Therapeutics’ network-driven drug discovery platform looks at the broader interactions within disease mechanisms

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use